It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...
According to the approved data and research by England NHS in the UK, people of Middle Eastern, Mediterranean, south and ...
With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...
Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...
Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...
Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...
As Vertex Pharmaceuticals Inc. heads toward the end of 2024, the Boston drugmaker is gearing up for two potential drug ...
CASGEVYâ„¢ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback